Abstract
Vitiligo is a chronic skin disease characterized by the appearance of white depigmented lesion due to a loss of melanocytes. The etiopathogenesis of vitiligo is not clear, but according to the neural theory of vitiligo, the direct and indirect effects of monoamine neurotransmitters cause melanocyte destruction and various studies have supported this theory. Many drugs have been related to the development of vitiligo, and the melanocytotoxic effects of the some of these drugs are thought to be related due to their effects on the monoaminergic system. Furthermore, a recent article reported the development of a localized loss of pigmentation after the application of a methylphenidate patch in a patient with attention-deficit/hyperactivity disorder (ADHD). Atomoxetine is an inhibitor of norepinephrine reuptake sites and is a drug that has been used for the treatment of ADHD. Here, we present a school-aged child with ADHD who displayed a vitiligo lesion following the initiation of atomoxetine. We further discuss the possible impact of the ADHD drugs on the development of vitiligo.
This is a preview of subscription content, log in via an institution to check access.
References
Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH et al (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699–711
Castanet J, Ortonne JP (1997) Pathophysiology of vitiligo. Clin Dermatol 15:845–885
Chu CY, Liu YL, Chiu HC, Jee SH (2006) Dopamine-induced apoptosis in human melanocytes involves generation of reactive oxygen species. Br J Dermatol 154:1071–1079
Cucchi MR, Frattini P, Santagostina G, Preda S, Orecchia G (2003) Catecholamines increase in the urine of non-segmental vitiligo especially during its active phase. Pigment Cell Res 16:111–116
Ding YS, Naganawa M, Gallezot JD, Nabulsi N, Lin SF, Ropchan J et al (2014) Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: implications on treatment of depression and ADHD. Neuroimage 86:164–171
Ghasri P, Gattu S, Saedi N, Ganesan AK (2012) Chemical leukoderma after the application of a transdermal methylphenidate patch. J Am Acad Dermatol 66:e237–e238
Jesinkey SR, Korrapati MC, Rasbach KA, Beeson CC, Schnellmann RG (2014) Atomoxetine prevents dexamethasone-induced skeletal muscle atrophy in mice. J Pharmacol Exp Ther 351:663–673
Kwon DY, Park MH, Oh K, Ryu HJ, Park KW (2010) Acute unilateral poliosis concurrent with trigeminal autonomic cephalalgia: a possible aetiological association. Australas J Dermatol 51:66–68
Ledbetter M (2006) Atomoxetine: a novel treatment for child and adult ADHD. Neuropsychiatr Dis Treat 2:455–466
Lee DY, Kim CR, Park JH, Lee JH (2011) The incidence of leukotrichia in segmental vitiligo: implication of poor response to medical treatment. Int J Dermatol 50:925–927
Mirbolooki MR, Upadhyay SK, Constantinescu CC, Pan ML, Mukherjee J (2014) Adrenergic pathway activation enhances brown adipose tissue metabolism: a [18F]FDG PET/CT study in mice. Nucl Med Biol 41:10–16
Modjtahedi BS, Alikhan A, Maibach HI, Schwab IR (2011) Diseases of periocular hair. Surv Ophthalmol 56:416–432
Namazi MR (2007) Neurogenic dysregulation, oxidative stress, autoimmunity, and melanocytorrhagy in vitiligo: can they be interconnected? Pigment Cell Res 20:360–363
Namazi MR (2008) Proton pump inhibitors may trigger vitiligo by rendering melanocytes prone to apoptosis. Br J Dermatol 158:844–845
Palit A, Inamadar AC (2012) Childhood vitiligo. J Dermatol Venereol Leprol 78:30–41
Roberts A, Kaye LC, Memon A, Parslew R, Kaye SB (2005) Unilateral poliosis of the eyelashes in children associated with vitiligo. J AAPOS 9:295–296
Sabaté M, Bosch A, Pedrós C, Figueras A (1999) Vitiligo associated with tolcapone and levodopa in a patient with Parkinson’s disease. Ann Pharmacother 33:1228–1229
Schallreuter KU (1995) Beta-adrenergic blocking drugs may exacerbate vitiligo. Br J Dermatol 132:168–169
Yaghoobi R, Omidian M, Bagherani N (2011) Vitiligo: a review of the published work. J Dermatol 38:419–431
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bilgiç, Ö., Bilgiç, A. Possible atomoxetine-induced vitiligo: a case report. ADHD Atten Def Hyp Disord 7, 179–181 (2015). https://doi.org/10.1007/s12402-015-0166-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12402-015-0166-1